Integra LifeSciences IART Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenues by Business | ||||||
| Specialty Surgery | $283.14M+0.9% | —— | —— | —— | $280.66M— | |
| Tissue Reconstruction | $108.78M+6.7% | —— | —— | —— | $101.99M— | |
| Operating Income (Loss) by Business | ||||||
| Specialty Surgery | $83.13M+15.1% | —— | —— | —— | $72.22M— | |
| Tissue Reconstruction | $20.27M+356% | —— | —— | —— | $4.44M— | |
| Cost of goods sold by Business | ||||||
| Specialty Surgery | $110.48M+0.6% | —— | —— | —— | $109.86M— | |
| Tissue Reconstruction | $37.46M-24.0% | —— | —— | —— | $49.27M— | |
| SG&A by Business | ||||||
| Specialty Surgery | $77.68M-7.3% | —— | —— | —— | $83.79M— | |
| Tissue Reconstruction | $43.53M+2.9% | —— | —— | —— | $42.3M— | |
| Costs and Expenses by Business | ||||||
| Specialty Surgery | $200.01M-4.0% | —— | —— | —— | $208.44M— | |
| Tissue Reconstruction | $88.52M-9.3% | —— | —— | —— | $97.55M— | |
| R&D by Business | ||||||
| Specialty Surgery | $11.85M-19.9% | —— | —— | —— | $14.8M— | |
| Tissue Reconstruction | $7.53M+26.1% | —— | —— | —— | $5.97M— | |
| Foreign currency translation by Business | ||||||
| Specialty Surgery | -$1.07M— | —— | —— | —— | —— | |
| Tissue Reconstruction | -$841K— | —— | —— | —— | —— | |
| Intangible asset amortization by Business | ||||||
| Specialty Surgery | $0— | —— | —— | —— | $0— | |
| Tissue Reconstruction | $0— | —— | —— | —— | $0— | |
| Goodwill by Business | ||||||
| Specialty Surgery | $343.1M— | $344.17M— | —— | —— | —— | |
| Tissue Reconstruction | $270.15M— | $270.99M— | —— | —— | —— | |
| Total Revenues by Product | ||||||
| ENT | $37.71M-2.8% | $44.82M+2.9% | $40.87M+0.7% | $41.89M+0.4% | $38.8M+296% | |
| Instruments | $47.23M-7.3% | $52.29M+2.5% | $50.15M-7.5% | $53.08M-2.7% | $50.95M+14.8% | |
| Neurosurgery | $198.2M+3.8% | $226.2M+2.8% | $201.56M+14.6% | $208.99M+1.7% | $190.91M-5.6% | |
| Private Label | $29.14M+7.1% | $31.64M+19.6% | $25.49M-13.9% | $26.9M-6.3% | $27.21M-13.8% | |
| Wound Reconstruction | $79.65M+6.5% | $79.97M-21.2% | $83.99M+4.4% | $84.75M-3.4% | $74.78M-7.5% | |
| Total Revenues by Geography | ||||||
| Asia Pacific | $45.21M+0.2% | $53.73M+21.9% | $42.68M+15.2% | $47.73M+3.9% | $45.11M-9.0% | |
| Europe | $39.96M+13.1% | $41.85M0.0% | $42.89M+24.8% | $42.59M+4.7% | $35.33M-15.1% | |
| Rest of World | $17.36M-13.2% | $18.96M-8.4% | $20.64M+7.4% | $18.97M-11.0% | $20.01M-7.0% | |
| United States | $289.38M+2.5% | $320.37M-4.7% | $295.85M+1.9% | $306.31M-1.3% | $282.22M+10.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Integra LifeSciences break its business down?
- Integra LifeSciences (IART) reports total revenues by business across 2 parts — Specialty Surgery and Tissue Reconstruction. Each is extracted from the segment footnotes and tracked over time.
- Where does Integra LifeSciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Integra LifeSciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
